Fundraising FoxArkVax
2 known investors
Find your way into ArkVax
Sign up to see every warm intro you have to ArkVax
- Paths you didn't know you had: your email and LinkedIn already hold routes to the ArkVax team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
ArkVax develops glycoconjugate vaccines for animal health using genetic engineering of bacterial cells, aiming to provide broader protection than current vaccines. Its technology targets antibacterial and zoonotic diseases to help combat antimicrobial resistance in both livestock and humans.
Founders & leadership
JC
Jon CuccuiFounderHe previously served as an Associate Professor of Glycoengineering and Glycobiology at the London School of Hygiene and Tropical Medicine, where he conducted vaccine development research.
Investors · 2
Frequently asked questions
- What does ArkVax do?
- ArkVax develops glycoconjugate vaccines for animal health using genetic engineering of bacterial cells, aiming to provide broader protection than current vaccines. Its technology targets antibacterial and zoonotic diseases to help combat antimicrobial resistance in both livestock and humans.
- Who founded ArkVax?
- ArkVax was founded by Jon Cuccui.
- Who are ArkVax's investors?
- ArkVax's investors include Future Planet Capital, UK Innovation & Science Seed Fund.